Tuzun, E. Et Al. 2017. HoxB3, a novel biomarker that predicts conversion to multiple sclerosis. 7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) , (Paris, France), 428-429.

Tuzun, E., Karaaslan, Z., Timirci-Kahraman, O., Ulusoy, C., Kucukali, C. I., Gunduz, T., ... Kurtuncu, M.(2017). HoxB3, a novel biomarker that predicts conversion to multiple sclerosis . 7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) (pp.428-429). Paris, France

Tuzun, E. Et Al. "HoxB3, a novel biomarker that predicts conversion to multiple sclerosis," 7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 2017

Tuzun, E. Et Al. "HoxB3, a novel biomarker that predicts conversion to multiple sclerosis." 7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) , Paris, France, pp.428-429, 2017

Tuzun, E. Et Al. (2017) . "HoxB3, a novel biomarker that predicts conversion to multiple sclerosis." 7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) , Paris, France, pp.428-429.

@conferencepaper{conferencepaper, author={E. Tuzun Et Al. }, title={HoxB3, a novel biomarker that predicts conversion to multiple sclerosis}, congress name={7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS)}, city={Paris}, country={France}, year={2017}, pages={428-429} }